GR970100477A - Νεα συνθεση - Google Patents

Νεα συνθεση

Info

Publication number
GR970100477A
GR970100477A GR970100477A GR970100477A GR970100477A GR 970100477 A GR970100477 A GR 970100477A GR 970100477 A GR970100477 A GR 970100477A GR 970100477 A GR970100477 A GR 970100477A GR 970100477 A GR970100477 A GR 970100477A
Authority
GR
Greece
Prior art keywords
novel formulation
formulation
budesonide
nose
treatment
Prior art date
Application number
GR970100477A
Other languages
English (en)
Other versions
GR1003011B (el
Inventor
Hans Nilsson
Gordon Santesson
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR970100477(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9604486A external-priority patent/SE9604486D0/xx
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of GR970100477A publication Critical patent/GR970100477A/el
Publication of GR1003011B publication Critical patent/GR1003011B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
GR970100477A 1996-12-05 1997-12-02 Νεα συνθεση GR1003011B (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604486A SE9604486D0 (sv) 1996-12-05 1996-12-05 Novel formulation
US08/846,960 US6291445B1 (en) 1996-12-05 1997-04-29 Low dose budesonide formulations and uses thereof

Publications (2)

Publication Number Publication Date
GR970100477A true GR970100477A (el) 1998-08-31
GR1003011B GR1003011B (el) 1998-11-20

Family

ID=26662810

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970100477A GR1003011B (el) 1996-12-05 1997-12-02 Νεα συνθεση

Country Status (23)

Country Link
US (2) US6686346B2 (el)
EP (1) EP0907365B1 (el)
JP (1) JP2000508675A (el)
CN (1) CN1168450C (el)
AT (2) ATE369118T1 (el)
AU (1) AU726515B2 (el)
BE (1) BE1011394A5 (el)
CZ (1) CZ295792B6 (el)
DE (2) DE69721766T2 (el)
DK (1) DK0907365T3 (el)
ES (1) ES2133130B1 (el)
FR (1) FR2756739B1 (el)
GR (1) GR1003011B (el)
HK (1) HK1020522A1 (el)
HU (1) HUP0000575A3 (el)
IE (1) IE970854A1 (el)
IL (1) IL125534A (el)
NL (1) NL1007706C2 (el)
NO (1) NO983555D0 (el)
NZ (1) NZ330925A (el)
PT (1) PT907365E (el)
TR (1) TR199801501T1 (el)
WO (1) WO1998024450A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) * 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
EP3354276B1 (en) 2007-11-13 2020-01-01 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
AU2009257390B2 (en) 2008-06-12 2014-09-04 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
WO2010042427A2 (en) 2008-10-06 2010-04-15 Microbial Defense Systems, Llc Antimicrobial composition and methods of making and using same
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
JP6463629B2 (ja) 2011-05-10 2019-02-06 ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ 抗菌性固体およびその製造方法
CN112516087B (zh) * 2020-12-24 2023-03-24 四川普锐特药业有限公司 布地奈德鼻喷剂及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983233A (en) * 1972-05-19 1976-09-28 Ab Bofors Compositions and method of treating with stereoisomeric mixtures of 2-unsymmetrical 16,17-methylenedioxy steroids
WO1992011280A1 (en) * 1990-12-20 1992-07-09 Instytut Farmaceutyczny Method of obtaining (22r) diastereoisomer of budesonide
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
WO1997001341A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US5509404A (en) 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983233A (en) * 1972-05-19 1976-09-28 Ab Bofors Compositions and method of treating with stereoisomeric mixtures of 2-unsymmetrical 16,17-methylenedioxy steroids
WO1992011280A1 (en) * 1990-12-20 1992-07-09 Instytut Farmaceutyczny Method of obtaining (22r) diastereoisomer of budesonide
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
WO1997001341A1 (en) * 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
WO1997046243A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine

Also Published As

Publication number Publication date
IL125534A0 (en) 1999-04-11
HK1020522A1 (en) 2000-05-12
GR1003011B (el) 1998-11-20
IL125534A (en) 2003-06-24
ATE239482T1 (de) 2003-05-15
CN1210467A (zh) 1999-03-10
NL1007706C2 (nl) 1998-09-22
HUP0000575A3 (en) 2001-03-28
IE970854A1 (en) 1998-10-07
NZ330925A (en) 2000-05-26
EP0907365A1 (en) 1999-04-14
DE69738000T2 (de) 2008-04-17
DE69738000D1 (de) 2007-09-20
CN1168450C (zh) 2004-09-29
NL1007706A1 (nl) 1998-06-08
FR2756739B1 (fr) 2000-04-28
JP2000508675A (ja) 2000-07-11
ES2133130B1 (es) 2000-03-01
US6986904B2 (en) 2006-01-17
DE69721766D1 (de) 2003-06-12
EP0907365B1 (en) 2003-05-07
AU726515B2 (en) 2000-11-09
AU5421198A (en) 1998-06-29
DE69721766T2 (de) 2004-03-04
US20040101486A1 (en) 2004-05-27
TR199801501T1 (xx) 1999-02-22
CZ295792B6 (cs) 2005-11-16
ATE369118T1 (de) 2007-08-15
NO983555L (no) 1998-08-03
WO1998024450A1 (en) 1998-06-11
FR2756739A1 (fr) 1998-06-12
CZ243798A3 (cs) 1998-11-11
US6686346B2 (en) 2004-02-03
US20020016315A1 (en) 2002-02-07
DK0907365T3 (da) 2003-08-04
PT907365E (pt) 2003-09-30
BE1011394A5 (fr) 1999-08-03
HUP0000575A2 (hu) 2000-10-28
NO983555D0 (no) 1998-08-03
ES2133130A1 (es) 1999-08-16

Similar Documents

Publication Publication Date Title
GR970100477A (el) Νεα συνθεση
SE9604486D0 (sv) Novel formulation
WO1994027589A3 (en) Antidepressant dosage form
GB2365772A (en) Factor
MY132705A (en) Novel compounds with analgesic effect
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
MX9605650A (es) Formulaciones de propionato de fluticasona.
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
MY128337A (en) New combination of steroids
CA2289717A1 (en) Novel therapy for constipation
UA41355C2 (uk) Засіб для лікування нейро-сніду
KR100213963B1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
IL120558A0 (en) New hormonal medicaments and their use for the correction of oestrogenic deficiencies
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
HUT60438A (en) Application of inhaled non-steroid inflammation reducers for potentiation of antireactive, antiasthmatic effect of inhaled henle's loop-diuretics
IL115652A0 (en) The use of vwf-containing concentrates as a therapy which is employed in combination with antithrombotic and fibrinolytic therapy and pharmaceutical compositions containing these
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
MY111755A (en) Use of 4'-iodo-4'- deoxydoxorubicin for the treatment of amyloidosis.
NZ268039A (en) Use of efaroxan in treating parkinson's disease
ZA945431B (en) Use of benzydamine in the treatment of pathological conditions caused by TNF
ZA978879B (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders.
TW360538B (en) Pharmaceutical composition containing 4'-iodo-4'-deoxydoxorubicin for treatment of amyloidosis
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees